Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease targets, for drug intervention. Also known as disease suppressors, genetic modifiers are genes that act to suppress or completely block the effect of a disease-causing mutated gene.
As a pioneer in the field, Scenic Biotech is building the largest proprietary data warehouse of genetic modifiers and has already identified a number of novel genetic modifiers for over a dozen inherited diseases.
This approach is enabling the development of disease modifying therapeutics for devastating diseases including inherited rare diseases and cancer.
The Company was founded in 2017 as a spin-out of the Netherlands Cancer Institute, and Oxford University. Through licensing from academic partners, and through our own strategy, Scenic has secured a strong Intellectual Property, covering its platform technology, its therapeutic targets, and composition of chemical matter/combinations for potential drug interventions.
Learn more about Scenic’s approach through this animation.
Scenic Biotech is headquartered in Amsterdam, the Netherlands.
Scenic Biotech has raised €8.0M in a Series A Financing backed by a Dutch-UK syndicate of Venture Capitalist investors that include BioGeneration Ventures, Inkef Capital, and Oxford Sciences Innovation. It has received €3.1 M non-dilutive Innovation Credit funding from the Dutch government RVO agency of the Ministry of Economic Affairs and Climate Policy.
Legal note – ‘Scenic Biotech’ refers to all companies within the Scenic group, comprising Scenic Holding BV and its two fully owned subsidiary companies: Scenic Immunology BV and Scenic Biotech BV.